Anticoagulation in venovenous extracorporeal membrane oxygenation

Area of Science:

• Critical Care Medicine
• Cardiopulmonary Support
• Hematology

Background:

• Venovenous extracorporeal membrane oxygenation (VV-ECMO) supports patients with severe acute respiratory distress syndrome (ARDS).
• Coagulation disorders, leading to bleeding and thrombosis, are common complications in VV-ECMO patients.
• These disorders stem from the device, the critical illness, and anticoagulation strategies.

Purpose of the Study:

• To emphasize the need for personalized hemostasis management in VV-ECMO patients.
• To highlight the importance of assessing the patient's coagulative state.
• To integrate underlying medical conditions and therapies into hemostasis decisions.

Main Methods:

• Review of current literature on VV-ECMO and coagulation.
• Analysis of factors influencing hemostasis in ECMO patients.
• Discussion of diagnostic and therapeutic strategies for managing coagulation.

Main Results:

• VV-ECMO is a vital treatment for ARDS, but carries significant bleeding and thrombotic risks.
• Coagulation abnormalities are multifactorial, involving device interactions, disease severity, and anticoagulation.
• A tailored approach to hemostasis is essential for optimizing patient outcomes.

Conclusions:

• Effective management of VV-ECMO requires a comprehensive understanding of coagulation.
• Personalized assessment of hemostasis, considering individual patient factors, is critical.
• Integrating clinical status and therapeutic interventions ensures safer and more effective ECMO support.